BiotechTube

ABT-494

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crohn's Disease (CD)

Conditions

Crohn's Disease (CD)

Trial Timeline

May 18, 2016 → Jul 18, 2025

NCT ID
NCT02782663

About ABT-494

ABT-494 is a phase 2 stage product being developed by AbbVie for Crohn's Disease (CD). The current trial status is completed. This product is registered under clinical trial identifier NCT02782663. Target conditions include Crohn's Disease (CD).

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02782663Phase 2Completed

Competing Products

20 competing products in Crohn's Disease (CD)

See all competitors
ProductCompanyStageHype Score
CT-P13 + RemicadeCelltrionPhase 3
77
CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13CelltrionPhase 1
33
CT-P13 SC (Infliximab)CelltrionPhase 3
77
CP-461Astellas PharmaPhase 2
52
E6011 2 mg/kg + E6011 5 mg/kg + E6011 10 mg/kg + E6011 15 mg/kgEisaiPhase 1/2
41
E6011 + PlaceboEisaiPhase 2
52
E6011 + PlaceboEisaiPhase 1
33
adalimumab + adalimumab + placeboEisaiPhase 2/3
65
adalimumabEisaiPhase 2/3
65
Mirikizumab + Mirikizumab + Ustekinumab + Ustekinumab + Placebo + PlaceboEli LillyPhase 3
77
MirikizumabEli LillyPhase 3
77
Mirikizumab + Mirikizumab + Tirzepatide + PlaceboEli LillyPhase 3
77
Mirikizumab + PlaceboEli LillyPhase 2
52
MirikizumabEli LillyPhase 3
77
Matching Placebo for Upadacitinib + UpadacitinibAbbViePhase 3
77
Adalimumab + PlaceboAbbViePhase 3
77
Upadacitinib + Placebo for UpadacitinibAbbViePhase 3
77
Placebo + ABT-494AbbViePhase 2
52
Risankizumab + ComparatorAbbViePre-clinical
23
placebo for risankizumab + risankizumab IV + risankizumab SCAbbViePhase 3
77

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85